(d) Effect on platelet function.

6. (Amended) A method according to Claim 1, in which the modulator is an activator, as herein defined.

8. (Amended) A method according to Claim 1, in which the modulator is an inhibitor, as herein defined.

9. (Amended) A method according to Claim 3, in which the modulator acts preferentially on non-neuronal cells.

10. (Amended) A method according to Claim 1, in which the modulator promotes the dephosphorylation of Ser-1177 and inhibits eNOS activity.

12. (Amended) A method according to Claim 1, in which the modulator promotes phosphorylation of nNOS or nNOSμ at Ser-1417.

13. (Amended) A method according to Claim 1, in which the modulator promotes dephosphorylation of nNOS or nNOSμ at Ser-1417.

Please add new claims 14-24, as follows:

14. (New) An antibody directed against eNOS, in which the eNOS is phosphorylated at Ser-1177 or at Thr-495.

15. (New) An antibody according to Claim 14, in which the eNOS is phosphorylated at Ser-1177.

16. (New) An antibody according to Claim 14, in which the eNOS is phosphorylated at Thr-495.

17. (New) An antibody according to Claim 14, in which the antibody is raised against a synthetic phosphopeptide comprising the sequence RIRTQSpFSLQER.

18. (New) An antibody according to Claim 14, in which the antibody is raised against a synthetic phosphopeptide comprising the sequence GITRKKTpFKEVANCV.

19. (New) An antibody according to Claim 14, which is a polyclonal antibody.

20. (New) An antibody according to Claim 14, which is a monoclonal antibody.

21. (New) An antibody according to Claim 14, labelled with a detectable marker.

22. (New) A method of detecting phosphorylation of eNOS, comprising the step of reacting a biological sample containing eNOS with an antibody according to claim 14.

23. (New) A method according to Claim 23, in which Ser-1177 is detected.